Modulation of the activity of chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib ('Iressa', ZD1839) in human cancer cell lines.

被引：0
|
作者：
Friedmann, BJ [1 ]
Caplin, M [1 ]
Hartley, JA [1 ]
Hochhauser, D [1 ]
机构：
[1] UCL, Royal Free & Univ Coll, Sch Med, Dept Oncol, London, England
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6094S / 6094S
页数：1
相关论文
共 50 条
  • [1] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors
    Blackledge, G
    Averbuch, S
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (03) : 566 - 572
  • [2] Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
    G Blackledge
    S Averbuch
    [J]. British Journal of Cancer, 2004, 90 : 566 - 572
  • [3] Activity of the epidermal growth factor receptor inhibitor gefitinib ('Iressa', ZD1839) in refractory non-small-cell lung cancer
    Parra, HS
    Cavina, R
    Zucali, P
    Campagnoli, E
    Latteri, F
    Biancofiore, G
    Abbadessa, G
    Morenghi, E
    Santoro, A
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S33 - S33
  • [4] Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839)
    Friedmann, B
    Caplin, M
    Hartley, JA
    Hochhauser, D
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (19) : 6476 - 6486
  • [5] Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer
    Santoro, A
    Cavina, R
    Latteri, F
    Zucali, PA
    Ginanni, V
    Campagnoli, E
    Ferrari, B
    Morenghi, E
    Pedicini, V
    Roncalli, A
    Alloisio, M
    Ravasi, G
    Parral, HJS
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (01) : 33 - 37
  • [6] Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
    van Doorn, R
    Kirtschig, G
    Scheffer, E
    Stoof, TJ
    Giaccone, G
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (03) : 598 - 601
  • [7] Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation
    Li, JS
    Kleeff, J
    Giese, N
    Büchler, MW
    Korc, M
    Friess, H
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 25 (01) : 203 - 210
  • [8] Clinically meaningful response to the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
    Gelibter, A
    Ceribelli, A
    Milella, M
    Mottolese, M
    Vocaturo, A
    Cognetti, F
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S28 - S28
  • [9] Cell growth after withdrawal of gefitinib ('Iressa', ZD1839) in human lung cancer cells
    Satoh, H
    Ishikawa, H
    Nakayama, M
    Fujiwara, M
    Ohtsuka, M
    Sekizawa, K
    [J]. ONCOLOGY REPORTS, 2004, 12 (03) : 615 - 619
  • [10] Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma
    Okano, Tetsuya
    Kondo, Tadashi
    Fujii, Kiyonaga
    Nishimura, Toshihide
    Takano, Toshimi
    Ohe, Yuichiro
    Tsuta, Koji
    Matsuno, Yoshihiro
    Gemma, Akihiko
    Kato, Harbumi
    Kudoh, Shoji
    Hirohashi, Setsuo
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (03) : 799 - 805
12345